-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $29

Benzinga·07/10/2025 11:41:52
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price target from $25 to $29.